Estrogen replacement is not normally recommended after ER positive breast cancer because large, randomized clinical trials have demonstrated that therapeutic estrogen receptor blockade, or suppression of estrogen biosynthesis, leads to improved breast cancer outcomes (reduced breast cancer relapse, improved breast cancer, and overall survival). This evidence concerns the gene ESR1 and breast cancer.